Skip to content

Dural Puncture Epidural Versus Epidural Anesthesia for Cesarean Delivery

Dural Puncture Epidural Versus Epidural Anesthesia for Cesarean Delivery: A Randomized, Double-blind Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03915574
Enrollment
280
Registered
2019-04-16
Start date
2019-05-09
Completion date
2023-04-01
Last updated
2023-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain Levels

Brief summary

This study will compare two anesthetics techniques called Dural Puncture Epidural (DPE) and Standard Epidural as to which of the two can provide faster and potentially better at providing pain relief for cesarean sections. It will also compare these two anesthetics techniques on the percentage of women who require additional drugs to control pain during their cesarean deliveries. The results of this study will help anesthesiologists know which anesthetic technique can provide faster and potentially better at providing pain relief for cesarean sections.

Detailed description

The aim of this study is to compare the onset time of anesthesia between standard epidural and Dural Puncture Epidural (DPE) for cesarean delivery. The study will hypothesize that a DPE technique with a 25-gauge spinal needle will have a faster onset and improved quality of surgical anesthesia when compared to a standard epidural. Participants will be blinded to which group they are being assigned. An unblinded anesthesiologist will insert the epidural or DPE based on randomization. After insertion of the epidural or DPE, a low dose local anesthetic infusion will be infused into the epidural catheter up until the time of surgery. This is the standard infusion used to provide pain relief in laboring women (bupivacaine 0.0625% with 2 mcg/ml fentanyl). In this way participants enrolled in the study would mimic anesthetic the conditions of a labor epidural. Participants will then move on to the next phase of the study. In this phase, the epidural pump will be discontinued, and anesthesia care will be conducted in the same manner as all cesarean deliveries under epidural extension anesthesia (this refers to the process of providing anesthesia using a pre-existing epidural/DPE that was inserted for the purpose of providing labor analgesia). Anesthesia will be induced in a standardized manner with 20 ml of 3% chloroprocaine. Motor and sensory block will be tested at the end of the epidural loading dose. Loss of sharp sensation will be measured using a blunt plastic neurotip® (Owen Mumford, USA) until a sensory bilateral block to the T6 dermatomal level has been reached. The T6 level measured at the xiphoid process will be marked bilaterally with a washable marker pen to guarantee the precision of the primary endpoint (which will be assumed when sensory block goes above T6). Sensory testing will be performed from caudad to cephalad (i.e. from blocked to unblocked dermatomes) to identify the first unblocked dermatome. To identify the level where the sensation of touch is first appreciated, the investigator will ask the question: Tell me when you feel the sensation of something sharp touching your skin. Both the motor and sensory block evaluations are part of the standard clinical care of patients receiving neuraxial anesthesia. The main difference for participants enrolled in the study is that the frequency of sensory assessments will be increased so that the onset of surgical anesthesia can be accurately documented (approximately every minute and then more frequently as the sensory block approaches the primary endpoints). A second anesthesiologist, blind to the type of block will manage the clinical care of the patient from the beginning of the study (after epidural catheter placement) and will administer the induction drug (prepared by that anesthesiologist as per SOC). There will be no difference in this clinician's care of the subject than if she were not enrolled in the study. This will assess the onset of anesthesia and manage all aspects of the subject's clinical care including the documentation of the local anesthetic (LA) solution administration timing and its clinical effects. The speed of onset will be assessed from the end of epidural test dose. This will be defined as time zero and the start of anesthesia. If required, intra-operative analgesia will be offered in the form of further epidural top-up, intravenous fentanyl, ketamine, nitrous oxide or replacement of neuraxial anesthesia/conversion into general anesthesia as the standard of care (SOC).

Interventions

DEVICE25G Dural Puncture Epidural

Dural puncture created with a 25 gauge spinal needle

Control group - standard epidural (no dural puncture)

Sponsors

University of Arkansas
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

140 mother-infant dyads (280 actual participants)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Singleton pregnancy * Gestation \> 36 weeks * ASA class II and III * Provides written consent * Infant of mother * Elective or non-urgent cesarean delivery

Exclusion criteria

* Patient refusal * Urgent/emergent cesarean sections * ASA and IV or above * Unable to understand English * Significant back surgery or scoliosis * Lethal fetal abnormality or likely to affect APGAR scores * Weight \> 120 kg * Height \< 150 cm * Allergy to study solutions

Design outcomes

Primary

MeasureTime frameDescription
Onset Time of Surgical Anesthesia2 hoursThe primary outcome will be the onset time of surgical anesthesia in seconds. This will be measured from the induction of anesthesia (as defined by the beginning of injection of the Induction 1 syringe) to the point at which sharp sensation is lost bilaterally at the T6 dermatomal level (as measured by a blunt plastic neurotip® (Owen Mumford, USA) device)

Secondary

MeasureTime frameDescription
Number of Participants With Inadequate Neuraxial Analgesia or Anesthesia2 hoursA composite outcome defined by failure to achieve at least a T10 bilateral sensory level pre-operatively (after 3 ml 1.5% lidocaine with 1:200,000 epinephrine 45 mg lidocaine and up to 20 ml of 0.0625% bupivacaine with 2mcg/ml fentanyl), the requirement for intraoperative analgesia supplementation, conversion to general anesthesia or repeat neuraxial procedure, or failure to achieve the primary outcome within 15 minutes between the two groups. Analyzed as a collapsed composite (any or none)

Other

MeasureTime frameDescription
Patient Satisfaction With Anesthetic Technique (Score)4 hoursOverall patient satisfaction score (units on a scale, 0 - 10)
Neonatal Requirement for Resuscitation2 hoursNeonatal Apgar scores (units on a scale, 0 - 10)
Neonatal Physiological Condition2 hoursUmbilical cord blood gases (pH measurement)
Requirement for Opioids in the First 24 Hours After Surgery24 hoursOpioid consumption measured in milligrams.
Maximum Pain During Surgery (Score)2 hoursMaximum pain visual analogue scale during surgery (units on a scale, 0 - 10)
Vasopressor Requirements During Surgery2 hoursmeasured in milligrams
Bromage Score (0 - 3 Scale)3 hoursMotor block assessment 0 - Able to move hip, knee, and ankle 1. \- unable to move hip, but able to move knee and ankle 2. \- unable to move hip and knee, but able to move ankle 3. \- unable to move hip, knee and ankle
Sensory Block Assessment3 hoursAssessed using sharp sensation at the midclavicular line on the abdomen and thorax Reported at the dermatomal level where sharp sensation is first felt
Anesthesia Adverse Effects24 hoursAccidental dural puncture, local anesthesia systemic toxicity, high spinal, post dural puncture headache
Anesthesia Side Effects2 hoursnausea, vomiting, itching (yes/no)
Cumulative Dose of Phenylephrine Measured in Milligram Required During Surgery2 hoursVasopressor requirements during surgery required to maintain systolic blood pressure within 15% of baseline

Countries

United States

Participant flow

Participants by arm

ArmCount
Dural Puncture Epidural
Participants will receive a dural puncture epidural block with a 25 gauge spinal needle followed by a standard epidural infusion (0.0625% bupivacaine + 2mcg/ml fentanyl) 25G Dural Puncture Epidural: Dural puncture created with a 25 gauge spinal needle
70
Standard Epidural
Participants will have standard epidural infusion followed by a standard epidural infusion (0.0625% bupivacaine + 2mcg/ml fentanyl) Standard Epidural: Control group - standard epidural (no dural puncture)
70
Total140

Baseline characteristics

CharacteristicDural Puncture EpiduralStandard EpiduralTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
70 Participants70 Participants140 Participants
Age, Continuous29.1 years
STANDARD_DEVIATION 5.3
31 years
STANDARD_DEVIATION 5.1
30.1 years
STANDARD_DEVIATION 5.2
Body Mass Index33.9 kg/m^2
STANDARD_DEVIATION 6.4
32.9 kg/m^2
STANDARD_DEVIATION 4.9
33.4 kg/m^2
STANDARD_DEVIATION 5.65
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
27 Participants19 Participants46 Participants
Race (NIH/OMB)
More than one race
0 Participants2 Participants2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
3 Participants0 Participants3 Participants
Race (NIH/OMB)
White
40 Participants45 Participants85 Participants
Sex: Female, Male
Female
70 Participants70 Participants140 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 700 / 66
other
Total, other adverse events
0 / 700 / 66
serious
Total, serious adverse events
0 / 700 / 66

Outcome results

Primary

Onset Time of Surgical Anesthesia

The primary outcome will be the onset time of surgical anesthesia in seconds. This will be measured from the induction of anesthesia (as defined by the beginning of injection of the Induction 1 syringe) to the point at which sharp sensation is lost bilaterally at the T6 dermatomal level (as measured by a blunt plastic neurotip® (Owen Mumford, USA) device)

Time frame: 2 hours

ArmMeasureValue (MEDIAN)
Dural Puncture EpiduralOnset Time of Surgical Anesthesia422 seconds
Standard EpiduralOnset Time of Surgical Anesthesia655 seconds
Secondary

Number of Participants With Inadequate Neuraxial Analgesia or Anesthesia

A composite outcome defined by failure to achieve at least a T10 bilateral sensory level pre-operatively (after 3 ml 1.5% lidocaine with 1:200,000 epinephrine 45 mg lidocaine and up to 20 ml of 0.0625% bupivacaine with 2mcg/ml fentanyl), the requirement for intraoperative analgesia supplementation, conversion to general anesthesia or repeat neuraxial procedure, or failure to achieve the primary outcome within 15 minutes between the two groups. Analyzed as a collapsed composite (any or none)

Time frame: 2 hours

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Dural Puncture EpiduralNumber of Participants With Inadequate Neuraxial Analgesia or Anesthesia11 Participants
Standard EpiduralNumber of Participants With Inadequate Neuraxial Analgesia or Anesthesia24 Participants
Other Pre-specified

Anesthesia Adverse Effects

Accidental dural puncture, local anesthesia systemic toxicity, high spinal, post dural puncture headache

Time frame: 24 hours

Other Pre-specified

Anesthesia Side Effects

nausea, vomiting, itching (yes/no)

Time frame: 2 hours

Other Pre-specified

Bromage Score (0 - 3 Scale)

Motor block assessment 0 - Able to move hip, knee, and ankle 1. \- unable to move hip, but able to move knee and ankle 2. \- unable to move hip and knee, but able to move ankle 3. \- unable to move hip, knee and ankle

Time frame: 3 hours

Other Pre-specified

Cumulative Dose of Phenylephrine Measured in Milligram Required During Surgery

Vasopressor requirements during surgery required to maintain systolic blood pressure within 15% of baseline

Time frame: 2 hours

Other Pre-specified

Maximum Pain During Surgery (Score)

Maximum pain visual analogue scale during surgery (units on a scale, 0 - 10)

Time frame: 2 hours

Other Pre-specified

Neonatal Physiological Condition

Umbilical cord blood gases (pH measurement)

Time frame: 2 hours

Other Pre-specified

Neonatal Requirement for Resuscitation

Neonatal Apgar scores (units on a scale, 0 - 10)

Time frame: 2 hours

Other Pre-specified

Patient Satisfaction With Anesthetic Technique (Score)

Overall patient satisfaction score (units on a scale, 0 - 10)

Time frame: 4 hours

Other Pre-specified

Requirement for Opioids in the First 24 Hours After Surgery

Opioid consumption measured in milligrams.

Time frame: 24 hours

Other Pre-specified

Sensory Block Assessment

Assessed using sharp sensation at the midclavicular line on the abdomen and thorax Reported at the dermatomal level where sharp sensation is first felt

Time frame: 3 hours

Other Pre-specified

Vasopressor Requirements During Surgery

measured in milligrams

Time frame: 2 hours

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026